相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
Alexander Marx et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Baudin et al.
ANNALS OF ONCOLOGY (2021)
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
Kyoichi Kaira et al.
CANCERS (2021)
Remission of Thymoma on Steroid Therapy in a Patient With Atypical Thymoma-Associated Multiorgan Autoimmunity: A Case Report and Literature Review
Ewa Wrona et al.
FRONTIERS IN IMMUNOLOGY (2021)
An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances
Valentina Tateo et al.
PHARMACEUTICALS (2021)
Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors
Zi-Ming Wang et al.
THORACIC CANCER (2021)
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)
F. Conforti et al.
ESMO OPEN (2021)
Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib
Daniel R. Principe et al.
ONCOLOGIST (2020)
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Jun Sato et al.
LANCET ONCOLOGY (2020)
Immunotherapy for thymoma
Marko Jakopovic et al.
JOURNAL OF THORACIC DISEASE (2020)
Octreotide in the treatment of malignant thymoma - Case report
Ondrej Sorejs et al.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2020)
Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge
Sara Pusceddu et al.
TUMORI JOURNAL (2019)
Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge
Sara Pusceddu et al.
TUMORI JOURNAL (2019)
Activation of the mTOR/Akt pathway in thymic epithelial cells derived from thymomas
Jean-Michel Maury et al.
PLOS ONE (2019)
Optimal management of thymic malignancies: current perspectives
Gabrielle Drevet et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
Federico Gatto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Octreotide, 40 years later
Steven W. J. Lamberts et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Ute Hennrich et al.
PHARMACEUTICALS (2019)
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Milan Radovich et al.
CANCER CELL (2018)
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy
Paolo Andrea Zucali et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Metastatic thymic carcinoid responds to chemoradiation and octreotide A case report
Zhu Mei et al.
MEDICINE (2018)
Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets
Franz Enkner et al.
PATHOLOGY & ONCOLOGY RESEARCH (2017)
P1.17-015 Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience
M. Ottaviano et al.
Journal of Thoracic Oncology (2017)
Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms
Irvin M. Modlin et al.
JOURNAL OF THORACIC DISEASE (2017)
Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network
Jordi Remon et al.
LUNG CANCER (2016)
Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study
Lukas Kirzinger et al.
PLOS ONE (2016)
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
N. Girard et al.
ANNALS OF ONCOLOGY (2015)
Thymoma Treated With 177Lu DOTATATE Induction and Maintenance PRRT
William Makis et al.
CLINICAL NUCLEAR MEDICINE (2015)
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
Anish Thomas et al.
LANCET ONCOLOGY (2015)
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial
Giovannella Palmieri et al.
FUTURE ONCOLOGY (2014)
Efficacy and Tolerability of long-acting Octreotide in the Treatment of Thymic Tumors Results of a Pilot Trial
Flavia Longo et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Imatinib mesylate in thymic epithelial malignancies
Giovannella Palmieri et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies
Giovannella Palmieri et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2012)
The role of somatostatin analogues in the treatment of advanced malignant thymomas: case report and review of the literature
L. Pettit et al.
BRITISH JOURNAL OF RADIOLOGY (2011)
Good Clinical Response to Imatinib Mesylate in Atypical Thymic Carcinoid With KIT Overexpression
Satoshi Hamada et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)
G. Palmieri et al.
ANNALS OF ONCOLOGY (2010)
THYMOMA-ASSOCIATED IMMUNODEFICIENCY: A SYNDROME CHARACTERIZED BY SEVERE ALTERATIONS IN NK, T AND B-CELLS AND PROGRESSIVE INCREASE IN NAIVE CD8+T CELLS
L. Vitiello et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2010)
Thymoma and Thymic Carcinoma Molecular Pathology and Targeted Therapy
Philipp Stroebel et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Glucocorticoid Production and Regulation in Thymus: Of Mice and Birds
Celso E. Gomez-Sanchez
ENDOCRINOLOGY (2009)
Octreotide LAR: safety and tolerability issues
Jan Bornschein et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Somatostatin receptor expression in thymic tumors
Diego Ferone et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Refractory Recurrent Thymoma Successfully Treated with Long-acting Somatostatin Analogue and Prednisolone
Jun Ito et al.
INTERNAL MEDICINE (2009)
Changes in thymus size, cellularity and relation between thymocyte subpopulations in young adult rats induced by Somatostatin-14
Danica M. Petrovic-Dergovic et al.
NEUROPEPTIDES (2007)
Advanced pediatric inoperable thymus carcinoma (Type C thymoma): Case report on a novel therapeutic approach
Gabriella P. Kertesz et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2007)
Complete regression of a thymoma to glucocorticoids, commenced for palliation of symptoms
Shaney Barratt et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2007)
Rapid regression of stage IVb invasive thymoma under palliative corticosteroid administration
Taiki Fujiwara et al.
GENERAL THORACIC AND CARDIOVASCULAR SURGERY (2007)
Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone
Kohei Yokoi et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Resolution of thymoma-related pure red cell aplasia after octreotide treatment
Renata Zaucha et al.
ACTA ONCOLOGICA (2007)
Thymoma followed by paroxysmal nocturnal hemoglobinuria: A unique clinical association in the context of multiorgan Autoimmunity with a potential role for CD8+T lymphocytes
Giovannella Palmieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Preoperative steroid pulse therapy for invasive thymoma - Clinical experience and mechanism of action
Y Kobayashi et al.
CANCER (2006)
Fatal immunodeficiency in a patient with thymoma and Good's syndrome
L Montella et al.
TUMORI JOURNAL (2005)
Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells
Y Funakoshi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium
RL Adams et al.
BRITISH JOURNAL OF CANCER (2005)
Dramatic responses to therapy in rare tumors
M Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets
EGR Lichtenauer-Kaligis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial
PJ Loehrer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Immunomodulatory activities of glucocorticoids: Insights from transgenesis and gene targeting
HM Reichardt
CURRENT PHARMACEUTICAL DESIGN (2004)
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib
P Strobel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mRNA levels: Evidence for direct and somatostatin-mediated effects
S Park et al.
NEUROENDOCRINOLOGY (2003)
B-cell lymphopenia and hypogammaglobulinemia in thymoma patients
L Montella et al.
ANNALS OF HEMATOLOGY (2003)
Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B lymphopenia
AM Masci et al.
BLOOD (2003)
Somatostatin analogs and prednisone in advanced refractory thymic tumors
G Palmieri et al.
CANCER (2002)
Modulatory effects of octreotide on anti-CD3 and dexamethasone-induced apoptosis of murine thymocytes
Z Trobonjaca et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2001)
Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells
R Mentlein et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
